1. Market Research
  2. > Healthcare Market Trends

The Path to Product Inclusion in Clinical Guidelines: Strategies for Success

  • February 2013
  • 49 pages
  • Firstword Pharma
Report ID: 1119708

Summary

Table of Contents





Clinical guidelines are taking hold in the practice of medicine. Though not always voluntarily followed in real-world patient care, they increasingly form the basis of formulary and reimbursement decisions, as well as the continuing medical education (CME) materials used by physicians.

In this guidelines-centric culture, it is more imperative than ever for drugs to be on the guidelines, and also harder than ever to influence the data that determines them.

Best practices around clinical guideline development call for independent analysis of raw data – untainted by financial gain or academic prestige.

In this tightly controlled and highly sensitive environment, what can Pharma do to maximise the credibility and visibility of its products?






Report Overview



The Path to Product Inclusion in Clinical Guidelines: Strategies for Success

If you’ve looked for information about clinical guidelines written with Pharma in mind, you’ve probably ended your search empty-handed.

The sensitive nature of the Pharma-clinical guideline relationship has made it difficult for Pharma to talk about this important topic.

This FirstWord Dossier report addresses this critical knowledge gap, and has been designed to get Pharma up to speed with the complexities of clinical guideline development and adherence, and to be prepared for future trends. The report also provides practical insights on how to increase visibility of medicines, even in an area that is beyond commercial influence.

In spite of most companies’ reluctance to speak on this subject, FirstWord has sourced illuminating commentary from Big Pharma representatives and prominent clinical guidelines experts.

Don’t miss this ground-breaking report – available now.






Learn about

Exclusive insights from industry experts
Clear documentation of how Pharma’s footprint is being eliminated from the appraisal of evidence
Explanation of the critical importance of clinical guidelines in rationalising the use of medicine
Cautionary tales of challenges to the guidelines
Detailed description of the latest standardised methods and best practices for research and guideline development worldwide (e.g., CONSORT, PRISMA, AGREE)
Up-to-date findings on adherence to guidelines
Handy global list of websites for referencing clinical guidelines







Key Benefits

Understand and effectively respond to the profound cultural shift towards evidence-based healthcare
Know how to gain a tactical advantage by considering a product’s place in clinical guidelines before development starts
Receive expert advice on how to position data and products for better visibility
Get up to speed with the new concept of “activation of evidence”
Hear how the full and open disclosure of clinical trial results is likely to become the norm rather than the exception
Learn how clinical guidelines are moving from demonstrating best practice to best value


Key Questions Answered

What can Pharma do to make best use of the evidence they have?
What do opinion leaders want from Pharma?
What are the major trends in guideline development, and how can we ensure that our scientific messaging is in line with that thinking?
Why don’t doctors always follow the guidelines?
How holy is the holy grail of evidence-based medicine?


Who Should Read This Report

Professionals with responsibilities for:

Brand Management
Marketing
Medical Education
Pharma Publications
Medical Affairs
Clinical Trials




Expert Views Include:


Charlie Buckwell, director of McCann Complete Medical
Dr Tobias Gantner, founder and CEO of The Healthcare Futurists and a market access professional in Germany
Adam Jacobs, director of the UK consultancy Dianthus Medical
Dr Philip Mackowiak, chief of the Medical Care Clinical Centre of the VA Maryland Health Care System
Jim Smeeding, president of the TPG National Payor Roundtable
Dr Allen Sniderman, Cardiologist, McGill University Health Centre, Montreal, Canada
Dr David Williams, senior pharmaceutical physician
Senior Executive, top 20 pharma


Key Quotes

“The perspective of people who know how to manage data and the pitfalls would be valuable on [guideline] committees and I think they would also mitigate the influences where there are conflicts of interest,” Dr. Philip Mackowiak, chief of the Medical Care Clinical Centre, VA Maryland Health Care System

“[The PPSA’s policy on KOL payments] suggests that anybody who works with a pharmaceutical company is somehow doing something wrong. We are not going to move forward. We are not going to advance medical science.” Dr. Maurie Markman, senior vice president of clinical affairs, Cancer Treatment Centres of America

“The only way forward is to look at the very early phase development work, which is about defining the clinical need around which you need to design your future products.” Charlie Buckwell, chief executive, McCann Complete Medical




Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Amrita helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Infectious Disease Testing Market 2021: A 74-Country Analysis--Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 59500
  • Industry report
  • May 2017
  • by Venture Planning Group

This unique 68-country survey from VPGMarketResearch.com provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well ...

Europe Infectious Disease Testing Market 2021: A 31-Country Analysis--Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 47500
  • Industry report
  • May 2017
  • by Venture Planning Group

This new report from VPGMarketResearch.com provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well as companies ...

Hematology and Flow Cytometry Analyzers and Reagents Market 2021: A 74-Country Analysis--Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 47500
  • Industry report
  • May 2017
  • by Venture Planning Group

This 74-country survey from VPGMarketResearch.com provides granular data and analysis not available elsewhere. The survey is designed to help current suppliers and potential market entrants identify and ...


Download Unlimited Documents from Trusted Public Sources

Cardiology and Neurology Industry in Canada

  • May 2017
    41 pages
  • Cardiology  

    Neurology  

    Health Care Pro...  

  • Canada  

    United States  

View report >

Smoking Statistics Industry in the US

  • May 2017
    28 pages
  • Smoking Statist...  

    Arthritis  

  • United States  

    World  

    North America  

View report >

Health Facility Industry in the UK

  • May 2017
    18 pages
  • United Kingdom  

View report >

ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.